Alan Tan, MD, presented “Metastatic Castrate Resistant Prostate Cancer – Immunotherapy and PARP Inhibitors” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Tan, Alan. “Metastatic Castrate Resistant Prostate Cancer – Immunotherapy and PARP Inhibitors.” October, 2024. Accessed Jan 2025. https://grandroundsinurology.com/metastatic-castrate-resistant-prostate-cancer-immunotherapy-and-parp-inhibitors/
Metastatic Castrate Resistant Prostate Cancer – Immunotherapy and PARP Inhibitors – Summary
Alan Tan, MD, discusses multiple advanced treatment options for prostate cancer, focusing on genomic testing, PARP inhibitors, and emerging immunotherapy strategies. His 26-minute presentation begins with data indicating that 12% of prostate cancer patients carry germline mutations, predominantly in the BRCA family, emphasizing the prognostic significance of BRCA alterations. Genomic testing advancements, particularly in homologous recombination repair (HRR) alterations, reveal actionable pathways in approximately 25-27% of cases. PARP inhibitors are highlighted for their efficacy in BRCA-mutated cancers, with the latest trials—PROpel, TALAPRO-2, and MAGNITUDE—demonstrating survival benefits in combination therapies.
Dr. Tan also addresses immunotherapy, with a compelling clinical example underscoring the transformative impact of pembrolizumab in an ultra-high tumor mutation burden case. He also examines T-cell engagers, which show promise in overcoming downregulated MHC expression, and early-phase trials for bispecific antibodies. Toxicity management in PARP inhibitors is discussed in detail.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
